Announcement PDF Change of AGM Date 2 September 2024 – Melbourne, Australia: PharmAust Limited (ASX:PAA) (PharmAust or the Company) advises that the date and time of the Company’s 2024 Annual General Meeting (AGM) has been changed to Wednesday, 9 October 2024 at 11.00am (AEDT). The change of date is to provide the Company with sufficient time to complete the Notice of Meeting, following additional work resulting from the Company’s transformation undertaken in late FY24 and the lodgement of the Company’s Appendix 4E and 2024 Annual Report on 30 August 2024. The Board looks forward to meeting shareholders at the AGM. Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be dispatched to shareholders in due course. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company’s website at: https://investorhub.pharmaust.com/announcements This announcement is authorised for release by the Board of Directors of PharmAust Limited. For further information, please contact: Dr Michael Thurn Managing Director investorenquiries@pharmaust.com P +61 (3) 9692 7222 W www.pharmaust.com Media: Jacky Pfenninger Sodali & Co jacky.pfenninger@sodali.com P 0447301111 About PharmAust Limited: PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic proteins are broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including ALS. The company announced positive top-line results for its Phase 1 MEND study in patients with ALS in February this year. MPL was recently selected for inclusion in the HEALEY ALS Platform Trial and anticipates commencing enrolment in Q4 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US Food and Drug Administration for monepantel for the treatment of ALS in 2026. In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.3 PharmAust Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205 Tel: +61 3 9692 7222 www.pharmaust.com 1 Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015 Jun;262(6):1447-54. doi: 10.1007/s00415-015-7731-6. Epub 2015 Apr 11. PMID: 25860344; PMCID: PMC4469087. 2 Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951. Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834. 3 https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market PharmAust Investor Hub: We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements. Access the investor hub by scanning the QR code or visiting: https://investorhub.pharmaust.com/ PharmAust Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205 Tel: +61 3 9692 7222 www.pharmaust.com